PLoS ONE (Jan 2013)

MYC deregulation in gastric cancer and its clinicopathological implications.

  • Carolina Rosal Teixeira de Souza,
  • Mariana Ferreira Leal,
  • Danielle Queiroz Calcagno,
  • Eliana Kelly Costa Sozinho,
  • Bárbara do Nascimento Borges,
  • Raquel Carvalho Montenegro,
  • Andrea Kely Campos Ribeiro Dos Santos,
  • Sidney Emanuel Batista Dos Santos,
  • Helem Ferreira Ribeiro,
  • Paulo Pimentel Assumpção,
  • Marília de Arruda Cardoso Smith,
  • Rommel Rodríguez Burbano

DOI
https://doi.org/10.1371/journal.pone.0064420
Journal volume & issue
Vol. 8, no. 5
p. e64420

Abstract

Read online

Our study investigated the relationship between MYC alterations and clinicopathological features in gastric cancers. We evaluated the effect of MYC mRNA expression and its protein immunoreactivity, as well as copy number variation, promoter DNA methylation, and point mutations, in 125 gastric adenocarcinoma and 67 paried non-neoplastic tissues. We observed that 77% of the tumors presented MYC immunoreactivity which was significantly associated with increased mRNA expression (p<0.05). These observations were associated with deeper tumor extension and the presence of metastasis (p<0.05). MYC protein expression was also more frequently observed in intestinal-type than in diffuse-type tumors (p<0.001). Additionally, MYC mRNA and protein expression were significantly associated with its copy number (p<0.05). The gain of MYC copies was associated with late-onset, intestinal-type, advanced tumor stage, and the presence of distant metastasis (p<0.05). A hypomethylated MYC promoter was detected in 86.4% of tumor samples. MYC hypomethylation was associated with diffuse-type, advanced tumor stage, deeper tumor extension, and the presence of lymph node metastasis (p<0.05). Moreover, eighteen tumor samples presented at least one known mutation. The presence of MYC mutations was associated with diffuse-type tumor (p<0.001). Our results showed that MYC deregulation was mainly associated with poor prognostic features and also reinforced the presence of different pathways involved in intestinal-type and diffuse-type gastric carcinogenesis. Thus, our findings suggest that MYC may be a useful marker for clinical stratification and prognosis.